Biocon inks deal with Juno Pharma in Canada

9 October 2023

India’s Biocon (BSE: 532523) has signed a partnership agreement with Canadian specialty pharma company Juno Pharmaceuticals, for the commercialization of its vertically integrated, complex formulation, liraglutide, a drug-device combination for the treatment and management of type 2 diabetes and obesity.

The total potential market for liraglutide in Canada is estimated to be around $100 million, based on IQVIA MAT Q2 2023 data.

Under the terms of this agreement, Biocon will be responsible for obtaining regulatory approval for liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market. Liraglutide is the active ingredient of Danish firm Novo Nordisk’s (NOV: N) obesity drug Saxenda and is sold under the brand name Victoza for diabetes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK